Loading stock data…
$6.16-0.11 (-1.75%)
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
Aura Biosciences, Inc. in the Healthcare sector is trading at $6.16 with a market capitalization of $639M. Wall Street consensus targets $16.60 (5 analysts), implying a +169.5% move over the next 12 months. The stock is currently 35% below its 52-week high of $9.54, remaining 7.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.07M↓ | -$34.87M↓ | -$27.24M↑ | -$27.91M↑ | -$28.61M |
| Net Income | -$45.64M↓ | -$33.69M↓ | -$25.56M↑ | -$26.13M↑ | -$27.02M |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs o...